Could your own immune cells fight ALS? early trial begins

NCT ID NCT06671236

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing whether a special type of immune cell, called regulatory T cells (Tregs), is safe for people with ALS. The cells are taken from each patient's own blood, multiplied in a lab, and then injected into the spinal fluid. The study will enroll 12 adults with ALS to check for side effects and find a safe dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
regulatory T cells (Tregs) made from the patient's own blood
What this could lead to
If safe, this could point toward a new way to slow or manage ALS by calming the immune system.
What could go wrong
This is a very early, small safety trial with only 12 people. It may not show any benefit, and side effects from the cell injection or the procedure itself are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital of Zhengzhou University

    RECRUITING

    Zhengzhou, Henan, 450052, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.